CSBR
Champions Oncology, Inc.
CSBR lost money over the past year, so it has no meaningful PE right now.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CSBR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
CSBR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CSBR PE Valuation
CSBR has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CSBR Forward outlook
There aren't enough analyst estimates for CSBR to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CSBR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | -138% |
| Q2 2026 | -$0.08 | -124% |
| Q1 2026 | -$0.15 | -134% |
| Q4 2025 | $0.18 | +$0.24 |
| Q3 2025 | $0.21 | +$0.47 |
| Q2 2025 | $0.33 | +$0.87 |
| Q1 2025 | $0.44 | +$1.16 |
| Q4 2024 | -$0.06 | +$0.65 |
CSBR has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CSBR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.2M | +8.8% |
| Q2 2026 | $13.8M | +12% |
| Q1 2026 | $16.6M | -2.8% |
| Q4 2025 | $15M | +11% |
| Q3 2025 | $14M | -0.5% |
| Q2 2025 | $12.4M | -12% |
| Q1 2025 | $17M | +42% |
| Q4 2024 | $13.5M | +17% |
CSBR's revenue is growing: $15M last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.7% | +1.1 points |
| Q2 2026 | -3.8% | +13 points |
| Q1 2026 | -1.7% | -28 points |
| Q4 2025 | 1.2% | -4.2 points |
| Q3 2025 | -3.8% | -13 points |
| Q2 2025 | -16% | -14 points |
| Q1 2025 | 26% | +48 points |
| Q4 2024 | 5.4% | +22 points |
CSBR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CSBR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CSBR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$547K | -199% |
| Q2 2026 | -$2.2M | -134% |
| Q1 2026 | -$1.4M | -407% |
| Q4 2025 | -$2M | -$1.6M |
| Q3 2025 | $554K | +78% |
| Q2 2025 | $6.6M | +$8.3M |
| Q1 2025 | $448K | +$1.5M |
| Q4 2024 | -$377K | -186% |
CSBR's free cash flow was −$6M over the past year, against $7M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CSBR on cash generation, producing positive trailing cash flow while its opponent burns cash.
CSBR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +65.2K shares |
| 1 year | +0.8% | +109K shares |
| 3 years | +2.9% | +391K shares |
| 5 years | +3.7% | +496K shares |
| Available history | +7.2% | +933K shares |
CSBR has 14M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $32,000 |
| Q3 2023 | $602,000 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CSBR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CSBR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.0x | Net Cash |
| Q2 2026 | -22.6x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -3.3x | Net Cash |
| Q4 2022 | -5.2x | Net Cash |
CSBR has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CSBR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 11.5 | Oversold |
CSBR's weekly RSI is 37 (neutral) and its Stochastic is 11 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CSBR PE vs Healthcare Sector
| Metric | CSBR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSBR has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CSBR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.79 | 2.9% below |
| 20 week MA | $5.17 | 10% below |
| 50 week MA | $5.83 | 20% below |
| 100 week MA | $6.81 | 32% below |
| 200 week MA | $6.01 | 23% below |
CSBR is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CSBR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.71 | $11.2 | +45% |
| 2021 | $11.2 | $8.04 | -28% |
| 2022 | $8.04 | $4.48 | -44% |
| 2023 | $4.48 | $5.62 | +25% |
| 2024 | $5.62 | $8.35 | +49% |
| 2025 | $8.35 | $6.98 | -16% |
| 2026 YTD | $6.98 | $4.65 | -33% |
CSBR has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.